Literature DB >> 12705493

Clinical features of galactokinase deficiency: a review of the literature.

A M Bosch1, H D Bakker, A H van Gennip, J V van Kempen, R J A Wanders, F A Wijburg.   

Abstract

Galactokinase deficiency (McKusick 230200) is a rare autosomal recessive inborn error of galactose metabolism. Cataract and, rarely, pseudotumor cerebri caused by galactitol accumulation seem to be the only consistently reported abnormalities in this disorder. We performed a literature search to obtain information on the clinical spectrum of galactokinase deficiency. A total of 25 publications were traced describing 55 galactokinase-deficient patients. Cataract was reported in most patients. Clinical abnormalities other than cataract were reported in 15 (35%) out of 43 cases on which information was available. However, all symptoms were reported infrequently and a causal relationship with the galactokinase deficiency is unlikely. As cataract and pseudotumor cerebri appear to be the sole complications of galactokinase deficiency, the outcome for patients with galactokinase deficiency is much better than for patients with classical galactosaemia (McKusick 230400), a more common autosomal recessive disorder of galactose metabolism caused by galactose-1-phosphate uridyltransferase (GALT; EC 2.7.7.12) deficiency. Long-term follow-up of patients with this disorder has shown that, in spite of a severely galactose-restricted diet, most patients develop abnormalities such as a disturbed mental and/or motor development, dyspraxia and hypergonadotropic hypogonadism. Endogenous production of galactose has been considered an important aetiological factor. Although damage may well occur in utero, available evidence suggests that damage will continue after birth. Inhibition of galactokinase may then be a promising approach for controlling damage in GALT-deficient patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12705493     DOI: 10.1023/a:1022875629436

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  30 in total

1.  Galactokinase deficiency presenting as pseudotumor cerebri.

Authors:  N Litman; A I Kanter; L Finberg
Journal:  J Pediatr       Date:  1975-03       Impact factor: 4.406

2.  Galactose metabolism in a patient with hereditary galactokinase deficiency.

Authors:  R Gitzelmann; H J Wells; S Segal
Journal:  Eur J Clin Invest       Date:  1974-04       Impact factor: 4.686

3.  Hereditary galactokinase deficiency.

Authors:  J G Cook; N A Don; T P Mann
Journal:  Arch Dis Child       Date:  1971-08       Impact factor: 3.791

4.  [Galactokinase defect in a newborn infant].

Authors:  F Linneweh; E Schaumlöffel; M Vetrella
Journal:  Klin Wochenschr       Date:  1970-01-01

5.  Deficiency of erythrocyte galactokinase in a patient with galactose diabetes.

Authors:  R Gitzelmann
Journal:  Lancet       Date:  1965-10-02       Impact factor: 79.321

6.  Novel mutations in the GALK1 gene in patients with galactokinase deficiency.

Authors:  M Hunter; D Angelicheva; H L Levy; S M Pueschel; L Kalaydjieva
Journal:  Hum Mutat       Date:  2001       Impact factor: 4.878

7.  A founder mutation in the GK1 gene is responsible for galactokinase deficiency in Roma (Gypsies).

Authors:  L Kalaydjieva; A Perez-Lezaun; D Angelicheva; S Onengut; D Dye; N U Bosshard; A Jordanova; A Savov; P Yanakiev; I Kremensky; B Radeva; J Hallmayer; A Markov; V Nedkova; I Tournev; L Aneva; R Gitzelmann
Journal:  Am J Hum Genet       Date:  1999-11       Impact factor: 11.025

8.  Recurrent sepsis with deficiencies of C2 and galactokinase.

Authors:  M S Borzy; L Wolff; A Gewurz; N R Buist; E Lovrien
Journal:  Am J Dis Child       Date:  1984-02

9.  Cloning of the galactokinase cDNA and identification of mutations in two families with cataracts.

Authors:  D Stambolian; Y Ai; D Sidjanin; K Nesburn; G Sathe; M Rosenberg; D J Bergsma
Journal:  Nat Genet       Date:  1995-07       Impact factor: 38.330

10.  Galactokinase deficiency: a case report.

Authors:  Ismail Kurt; Muhittin Serdar; Fatih Mutlu; Atilla Bayer; J T Allen; Turker Kutluay
Journal:  J Pediatr Ophthalmol Strabismus       Date:  2002 Jan-Feb       Impact factor: 1.402

View more
  30 in total

1.  Structure-activity analysis and cell-based optimization of human galactokinase inhibitors.

Authors:  Si Odejinmi; Rg Rascon; M Tang; H Vankayalapati; K Lai
Journal:  ACS Med Chem Lett       Date:  2011-09-08       Impact factor: 4.345

2.  Altered cofactor binding affects stability and activity of human UDP-galactose 4'-epimerase: implications for type III galactosemia.

Authors:  Thomas J McCorvie; Ying Liu; Andrew Frazer; Tyler J Gleason; Judith L Fridovich-Keil; David J Timson
Journal:  Biochim Biophys Acta       Date:  2012-05-18

3.  Galactokinase deficiency in a patient with congenital hyperinsulinism.

Authors:  Mashbat Bayarchimeg; Dunia Ismail; Amanda Lam; Derek Burk; Jeremy Kirk; Wolfgang Hogler; Sarah E Flanagan; Sian Ellard; Khalid Hussain
Journal:  JIMD Rep       Date:  2011-12-13

4.  Cataract and early nystagmus due to galactokinase deficiency.

Authors:  Vladimir Bzduch; Dana Tomcikova; Anton Gerinec; Darina Behulova
Journal:  J Inherit Metab Dis       Date:  2017-04-20       Impact factor: 4.982

Review 5.  Classical galactosaemia revisited.

Authors:  Annet M Bosch
Journal:  J Inherit Metab Dis       Date:  2006-07-11       Impact factor: 4.982

Review 6.  Cat-Map: putting cataract on the map.

Authors:  Alan Shiels; Thomas M Bennett; J Fielding Hejtmancik
Journal:  Mol Vis       Date:  2010-10-08       Impact factor: 2.367

7.  Etiological analysis of neurodevelopmental disabilities: single-center eight-year clinical experience in south China.

Authors:  Li Guo; Bing-Xiao Li; Mei Deng; Fang Wen; Jian-Hui Jiang; Yue-Qiu Tan; Yuan-Zong Song; Zhen-Huan Liu; Chun-Hua Zhang; Keiko Kobayashi; Zi-Neng Wang
Journal:  J Biomed Biotechnol       Date:  2010-09-26

8.  pH-rate profiles support a general base mechanism for galactokinase (Lactococcus lactis).

Authors:  Laurie A Reinhardt; James B Thoden; Greg S Peters; Hazel M Holden; W W Cleland
Journal:  FEBS Lett       Date:  2013-07-19       Impact factor: 4.124

9.  High-throughput screening for human galactokinase inhibitors.

Authors:  Klaas J Wierenga; Kent Lai; Peter Buchwald; Manshu Tang
Journal:  J Biomol Screen       Date:  2008-05-19

Review 10.  Galactose toxicity in animals.

Authors:  Kent Lai; Louis J Elsas; Klaas J Wierenga
Journal:  IUBMB Life       Date:  2009-11       Impact factor: 3.885

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.